User:Neurotip/Neuropathy/Neuropathic pain

From Wikipedia, the free encyclopedia

According to the most widely accepted definition, neuropathic pain is "initiated or caused by a primary lesion or dysfunction in the nervous system."[1] Neuropathic pain cannot be explained by a single disease process or a single specific location of damage.

Neuropathic pain may be associated with abnormal sensations called dysesthesias, which occur spontaneously and allodynias that occur in response to external stimuli. Neuropathic pain may have continuous and/or episodic (paroxysmal) components. The latter are likened to an electric shock. Common qualities of neuropathic pain includes burning or coldness, "pins and needles" sensations, numbness and itching. Nociceptive pain is more commonly described as aching.

As much as 7% to 8% of the population is affected and in 5% it may be severe.[2][3] Neuropathic pain may result from disorders of the peripheral nervous system or the central nervous system (brain and spinal cord). Thus, neuropathic pain may be divided into peripheral neuropathic pain, central neuropathic pain, or mixed (peripheral and central) neuropathic pain.

Central neuropathic pain is found in spinal cord injury, multiple sclerosis, and some strokes. Fibromyalgia, a disorder of chronic widespread pain, is potentially a central pain disorder and is responsive to medications that are effective for neuropathic pain.[4]

Aside from diabetes (see Diabetic neuropathy) and other metabolic conditions, the common causes of painful peripheral neuropathies are herpes zoster infection, HIV-related neuropathies, nutritional deficiencies, toxins, remote manifestations of malignancies, genetic, and immune mediated disorders.[5][6]

Neuropathic pain is common in cancer as a direct result of cancer on peripheral nerves (e.g., compression by a tumor), or as a side effect of chemotherapy[7][8] , radiation injury or surgery.

Mechanisms of neuropathic pain[edit]

The starting point for neuropathic pain is a lesion or dysfunction within the somatosensory system. Current knowledge regarding the mechanisms of neuropathic pain is incomplete and is biased by a focus on animal models of peripheral nerve injury.

Peripheral Mechanisms[edit]

Under normal circumstances, pain sensations are carried by unmyelinated and thinly myelinated nerve fibers, designated C-fibers and A-delta fibers respectively. After a peripheral nerve lesion, a neuroma may develop at the stump. The neurons become unusually sensitive and develop spontaneous pathological activity, abnormal excitability, and elevated sensitivity to chemical, thermal and mechanical stimuli. This phenomenon is called "peripheral sensitization".

Central Mechanisms[edit]

The dorsal horn neurons give rise to the spinothalamic tract (STT), which constitutes the major ascending nociceptive pathway. As a consequence of ongoing spontaneous activity arising in the periphery, STT neurons develop an increased background activity, enlarged receptive field and increased responses to afferent impulses, including normally innocuous tactile stimuli. This phenomenon is called central sensitization. Central sensitization has been proposed as an important mechanism of persistent neuropathic pain.

Other mechanisms, however, may take place at the central level after peripheral nerve damage. The loss of afferent signals induces functional changes in dorsal horn neurons. A decrease in the large fiber input decreases activity of interneurons inhibiting nociceptive neurons i.e. loss of afferent inhibition. Nociceptive pain can be described as the one that can occur in our everyday life as an aftermath of a simple insult or injury. The mechanism for such type of pain can be generated by transduction, which converts the stimulus into electrical activity in specialized nociceptive primary afferent nerves.[9] Hypoactivity of the descending antinociceptive systems or loss of descending inhibition may be another factor. With loss of neuronal input (deafferentation) the STT neurons begin to fire spontaneously, a phenomenon designated "deafferentation hypersensitivity.”

Non-neural glial cells may play a role in central sensitization. Peripheral nerve injury induces glial to releasing glial proinflammatory cytokines and glutamate which, in turn influence neurons.[10]

Mechanisms at light-microscopic and submicroscopic levels[edit]

The phenomenon described above are dependent on changes at light-microscopic and submicroscopic levels. Aberrant regeneration, altered expression of ion channels, changes in neurotransmitters and their receptors as well as altered gene expression in response to neural input are at play.[11]

Treatments for neuropathic pain[edit]

Neuropathic pain can be very difficult to treat with only some 40-60% of patients achieving partial relief.[12]

In addition to the work of Dworkin, O'Connor and Backonja et al., cited above, there have been several recent attempts to derive guidelines for pharmacological therapy.[13][14] These have combined evidence from randomized controlled trials with expert opinion.

Determining the best treatment for individual patients remains challenging. Attempts to translate scientific studies into best practices are limited by factors such as differences in reference populations and a lack of head-to-head studies. Furthermore, multi-drug combinations and the needs of special populations, such as children, require more study.

It is common practice in medicine to designate classes of medication according to their most common or familiar use e.g. as "antidepressants" and "anti-epileptic drugs" (AED's). These drugs have alternate uses to treat pain because the human nervous system employs common mechanisms for different functions, for example ion channels for impulse generation and neurotransmitters for cell-to-cell signaling.

Favored treatments are certain antidepressants e.g. tricyclics and selective serotonin-norepinephrine re-uptake inhibitors (SNRI's), anticonvulsants, especially pregabalin (Lyrica) and gabapentin (Neurontin), and topical lidocaine. Opioid analgesics and tramadol are recognized as useful agents but are not recommended as first line treatments. Many of the pharmacologic treatments for chronic neuropathic pain decrease the sensitivity of nociceptive receptors, or desensitize C fibers such that they transmit fewer signals.

Some drugs may exert their influence through descending pain modulating pathways. These descending pain modulating pathways originate in the brainstem.

Antidepressants[edit]

Main article: Antidepressants

The functioning of antidepressants is different in neuropathic pain from that observed in depression. Activation of descending norepinephrinergic and serotonergic pathways to the spinal cord limit pain signals ascending to the brain. Antidepressants will relieve neuropathic pain in non-depressed persons.

In animal models of neuropathic pain it has been found that compounds which only block serotonin reuptake do not improve neuropathic pain.[15][16][17][18][19][20][21][22] Similarly, compounds that only block norepinephrine reuptake also do not improve neuropathic pain. Compounds such as duloxetine, venlafaxine, and milnacipran that block both serotonin reuptake and norepinephrine reuptake do improve neuropathic pain.

Tricyclic antidepressants may also work on sodium channels in peripheral nerves.

Anticonvulsants[edit]

Main article: Anticonvulsants

Pregabalin (Lyrica) and gabapentin (Neurontin) work by blocking specific calcium channels on neurons. The actions of the anticonvulsants carbamazepine (Tegretol) and oxcarbazepine (Trileptal), especially effective on trigeminal neuralgia, are principally on sodium channels.

Lamotrigine may have a special role in treating two conditions for which there are few alternatives, namely post stroke pain and HIV/AIDS-related neuropathy in that subgroup on antiretroviral therapy.[23]

Opioids[edit]

Main article: Opioids

Opioids, also known as narcotics, are increasingly recognized as important treatment options for chronic pain. They are not considered first line treatments in neuropathic pain but remain the most consistently effective class of drugs for this condition. Opioids must be used only in appropriate individuals and under close medical supervision.

Several opioids, particularly methadone have NMDA antagonist activity in addition to their µ-opioid agonist properties.

Methadone and ketobemidone possess NMDA antagonsism. Methadone does so because it is a racemic mixture; only the l-isomer is a potent µ-opioid agonist.[24]

There is little evidence to indicate that one strong opioid is more effective than another. Expert opinion leans toward the use of methadone for neuropathic pain, in part because of NMDA antagonism. It is reasonable to base the choice of opioid on other factors.[25]

Topical agents[edit]

In some forms of neuropathy, especially post-herpes neuralgia, the topical application of local anesthetics such as lidocaine can provide relief. A transdermal patch containing lidocaine is available commercially in some countries.

Repeated topical applications of capsaicin, are followed by a prolonged period of reduced skin sensibility referred to as desensitization, or nociceptor inactivation. Capsaicin not only depletes substance P but also results in a reversible degeneration of epidermal nerve fibers.[26] Nevertheless, benefits appear to be modest.[27]

Cannabinoids[edit]

Marijuana and its active ingredients are called cannabinoids. Unfortunately, strongly held beliefs make discussion of the appropriate use of these substances, in a medical context, difficult.[28] Similar considerations apply to opioids.

A recent study showed smoked marijuana is beneficial in treating symptoms of HIV-associated peripheral neuropathy.[29] Nabilone is an artificial cannabinoid which is significantly more potent than delta-9-tetrahydrocannabinol (THC). Nabilone produces less relief of chronic neuropathic pain and had slightly more side effects than dihydrocodeine.[30]

The predominant adverse effects are CNS depression and cardiovascular effects which are mild and well tolerated but, psychoactive side effects limit their use.[31] A complicating issue may be a narrow therapeutic window; lower doses decrease pain but higher doses have the opposite effect.[32]

Sativex, a fixed dose combination of delta-9-tetrahydrocannabinol (THC) and cannabidiol, is sold as an oromucosal spray. The product is approved in Canada as adjunctive treatment for the symptomatic relief of neuropathic pain in multiple sclerosis, and for cancer related pain.[33]

Long-term studies are needed to assess the probability of weight gain,[34] unwanted psychological influences and other adverse effects.

Botulinum Toxin Type A (Botox, BTX-A)[edit]

Main article: Botulinum toxin

Botulinum Toxin Type A (BTX-A) is best know by its trade name, Botox. Local intradermal injection of BTX-A is helpful in chronic focal painful neuropathies. The analgesic effects are not dependent on changes in muscle tone. Benefits persist for at least 14 weeks from the time of administration.[35]

The utility of BTX-A in other painful conditions remains to be established.[36]

NMDA antagonism[edit]

The N-methyl-D-aspartate (NMDA) receptor seems to play a major role in neuropathic pain and in the development of opioid tolerance.Dextromethorphan is an NMDA antagonist at high doses.Experiments in both animals and humans have established that NMDA antagonists such as ketamine and dextromethorphan can alleviate neuropathic pain and reverse opioid tolerance.[37] Unfortunately, only a few NMDA antagonists are clinically available and their use is limited by unacceptable side effects.

Reducing sympathetic nervous stimulation[edit]

In some neuropathic pain syndromes, "crosstalk" occurs between descending sympathetic nerves and ascending sensory nerves. Increases in sympathetic nervous system activity result in an increase of pain; this is known as sympathetically-mediated pain.

Lesioning operations on the sympathetic branch of the autonomic nervous system are sometimes carried out.

Dietary supplements[edit]

There are two dietary supplements that have clinical evidence showing them to be effective treatments of diabetic neuropathy; alpha lipoic acid and benfotiamine.[38]

A 2007 review of studies found that injected (parenteral) administration of alpha lipoic acid (ALA) was found to reduce the various symptoms of peripheral diabetic neuropathy.[39] While some studies on orally administered ALA had suggested a reduction in both the positive symptoms of diabetic neuropathy (including stabbing and burning pain) as well as neuropathic deficits (paresthesia),[40] the metanalysis showed "more conflicting data whether it improves sensory symptoms or just neuropathic deficits alone".[39] There is some limited evidence that ALA is also helpful in some other non-diabetic neuropathies.[41]

Benfotiamine is a lipid-soluble form of thiamine that has several placebo-controlled double-blind trials proving efficacy in treating neuropathy and various other diabetic comorbidities.[42][43]

Other modalities[edit]

In addition to pharmacological treatment several other modalities are commonly recommended.[44] While lacking adequate double blind trials, these have shown to reduce pain and improve patient quality of life for chronic neuropathic pain: chiropractic, yoga, massage, meditation, cognitive therapy,[45] and prescribed exercise. Some pain management specialists will try acupuncture, with variable results.

Transcutaneous electrical nerve stimulation (TENS) may be worth considering in chronic neurogenic pain. TENS, with certain electrical waveforms, appears to have an acupuncture-like function.

Infrared photo therapy has been used to treat neuropathic symptoms.[46] However, recent work has cast doubt on the value of this approach.[47]

Neuromodulators[edit]

Neuromodulation is a field of science, medicine and bioengineering that encompasses both implantable and non-implantable technologies (electrical and chemical) for treatment purposes.[48]

Implanted devices are expensive and carry the risk of complications. Available studies have focused on conditions having a different prevalence than neuropathic pain patients in general. More research is needed to define the range of conditions for which they might be beneficial.

Spinal cord stimulators and implanted spinal pumps[edit]

Spinal cord stimulators, use electrodes placed adjacent to, but outside the spinal cord. The overall complication rate is one-third, most commonly due to lead migration or breakage. Lack of pain relief sometimes prompts device removal.[49]

Infusion pumps deliver medication directly to the fluid filled (subarachnoid) space surrounding the spinal cord. Opioids alone or opioids with adjunctive medication (either a local anesthetic or clonidine) or more recently ziconotide[50] are infused. Complications such as, serious infection (meningitis), urinary retention, hormonal disturbance and intrathecal granuloma formation have been noted.

There are no randomized studies of infusion pumps. For selected patients 50% or greater pain relief is achieved in 38% to 56% at six months but declines with the passage of time.[51] These results must be viewed skeptically since placebo effects cannot be evaluated.

Motor cortex stimulation[edit]

Stimulation of the primary motor cortex through electrodes placed within the skull but outside the thick meningeal membrane (dura) has been used to treat pain. The level of stimulation is below that for motor stimulation. As compared with spinal stimulation, which requires a noticeable tingling (paresthesia) for benefit, the only palpable effect is pain relief.[52][53]

Deep Brain Stimulation[edit]

The best long-term results with deep brain stimulation have been reported with targets in the periventricular/periaqueductal grey matter (79%), or the periventricular/periaqueductal grey matter plus thalamus and/or internal capsule (87%).[54] There is a significant complication rate which increase over time.[55] [] Error: {{Lang}}: no text (help)

References[edit]

  1. ^ Bogduk, Nikolai; Merskey, Harold (1994). Classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms (2nd ed.). Seattle: IASP Press. p. 212. ISBN 0931092051.{{cite book}}: CS1 maint: multiple names: authors list (link)
  2. ^ Torrance N, Smith BH, Bennett MI, Lee AJ (April 2006). "The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey". J Pain. 7 (4): 281–9. doi:10.1016/j.jpain.2005.11.008. PMID 16618472.{{cite journal}}: CS1 maint: date and year (link) CS1 maint: multiple names: authors list (link)
  3. ^ Bouhassira D, Lantéri-Minet M, Attal N, Laurent B, Touboul C (June 2008). "Prevalence of chronic pain with neuropathic characteristics in the general population" (PDF). Pain. 136 (3): 380–7. doi:10.1016/j.pain.2007.08.013. PMID 17888574. S2CID 599627.{{cite journal}}: CS1 maint: date and year (link) CS1 maint: multiple names: authors list (link)
  4. ^ Dworkin RH, Fields HL (2005). "Fibromyalgia from the perspective of neuropathic pain". J Rheumatol Suppl. 75: 1–5. PMID 16078355.
  5. ^ Portenoy RK (1989). "Painful polyneuropathy". Neurol Clin. 7 (2): 265–88. doi:10.1016/S0733-8619(18)30813-2. PMID 2566901.
  6. ^ Vaillancourt PD, Langevin HM (1999). "Painful peripheral neuropathies". Med. Clin. North Am. 83 (3): 627–42, vi. doi:10.1016/S0025-7125(05)70127-9. PMID 10386118.
  7. ^ [1] Chemotherapy-induced Peripheral Neuropathy Fact Sheet, Retrieved on 29 December 2008
  8. ^ [2] Cancerbackup, Macmillan Cancer Support, Peripheral neuropathy, Retrieved on 29 December 2008
  9. ^ Guddin, J.A. Expanding Our Understanding of Central Sensitization. 'Medscape1994-2008. [3].
  10. ^ Wieseler-Frank J, Maier SF, Watkins LR (2005). "Central proinflammatory cytokines and pain enhancement". Neuro-Signals. 14 (4): 166–74. doi:10.1159/000087655. PMID 16215299. S2CID 3467891.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  11. ^ Truini A, Cruccu G (May 2006). "Pathophysiological mechanisms of neuropathic pain". Neurol. Sci. 27 Suppl 2: S179–82. doi:10.1007/s10072-006-0597-8. PMID 16688626. S2CID 28736907.{{cite journal}}: CS1 maint: date and year (link)
  12. ^ Dworkin RH, O'Connor AB, Backonja M; et al. (2007). "Pharmacologic management of neuropathic pain: evidence-based recommendations". Pain. 132 (3): 237–51. doi:10.1016/j.pain.2007.08.033. PMID 17920770. S2CID 9333155. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  13. ^ Attal N, Cruccu G, Haanpää M; et al. (2006). "EFNS guidelines on pharmacological treatment of neuropathic pain". Eur. J. Neurol. 13 (11): 1153–69. doi:10.1111/j.1468-1331.2006.01511.x. PMID 17038030. S2CID 15446990. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  14. ^ Moulin DE, Clark AJ, Gilron I; et al. (2007). "Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society". Pain Res Manag. 12 (1): 13–21. doi:10.1155/2007/730785. PMC 2670721. PMID 17372630. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  15. ^ Bennett G, Xie Y (1988). "A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man". Pain. 33 (1): 87–107. doi:10.1016/0304-3959(88)90209-6. PMID 2837713. S2CID 22942169.
  16. ^ Seltzer Z, Dubner R, Shir Y (1990). "A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury". Pain. 43 (2): 205–218. doi:10.1016/0304-3959(90)91074-S. PMID 1982347. S2CID 10540235.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  17. ^ Kim S, Chung J (1992). "An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat". Pain. 50 (3): 355–63. doi:10.1016/0304-3959(92)90041-9. PMID 1333581. S2CID 216059787.
  18. ^ Malmberg A, Basbaum A (1998). "Partial sciatic nerve injury in the mouse as a model of neuropathic pain: behavioral and neuroanatomical correlates". Pain. 76 (1–2): 215–22. doi:10.1016/S0304-3959(98)00045-1. PMID 9696476. S2CID 23878913.
  19. ^ Sung B, Na H, Kim Y, Yoon Y, Han H, Nahm S, Hong S (1998). "Supraspinal involvement in the production of mechanical allodynia by spinal nerve injury in rats". Neurosci. Lett. 246 (2): 117–9. doi:10.1016/S0304-3940(98)00235-3. PMID 9627194. S2CID 36857086.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  20. ^ Lee B, Won R, Baik E, Lee S, Moon C (2000). "An animal model of neuropathic pain employing injury to the sciatic nerve branches". NeuroReport. 11 (4): 657–61. doi:10.1097/00001756-200003200-00002. PMID 10757496. S2CID 40457392.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  21. ^ Decosterd I, Woolf C (2000). "Spared nerve injury: an animal model of persistent peripheral neuropathic pain". Pain. 87 (2): 149–58. doi:10.1016/S0304-3959(00)00276-1. PMID 10924808. S2CID 24918287.
  22. ^ Vadakkan K, Jia Y, Zhuo M (2005). "A behavioral model of neuropathic pain induced by ligation of the common peroneal nerve in mice". The Journal of Pain: Official Journal of the American Pain Society. 6 (11): 747–56. doi:10.1016/j.jpain.2005.07.005. PMID 16275599.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  23. ^ Wiffen PJ, Rees J. Lamotrigine for acute and chronic pain. Cochrane Database Syst Rev. 2007;(2):CD006044.
  24. ^ Davis AM, Inturrisi CE (1999). "d-Methadone blocks morphine tolerance and N-methyl-D-aspartate-induced hyperalgesia". J. Pharmacol. Exp. Ther. 289 (2): 1048–53. PMID 10215686.
  25. ^ Bruera E, Palmer JL, Bosnjak S; et al. (2004). "Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study". J. Clin. Oncol. 22 (1): 185–92. doi:10.1200/JCO.2004.03.172. PMID 14701781. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  26. ^ Nolano M, Simone DA, Wendelschafer-Crabb G, Johnson T, Hazen E, Kennedy WR (1999). "Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation". Pain. 81 (1–2): 135–45. doi:10.1016/S0304-3959(99)00007-X. PMID 10353501. S2CID 8952555.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  27. ^ Finnerup NB, Otto M, Jensen TS, Sindrup SH (2007). "An evidence-based algorithm for the treatment of neuropathic pain". MedGenMed. 9 (2): 36. PMC 1994866. PMID 17955091.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  28. ^ Ponto LL (May 2006). "Challenges of marijuana research". Brain. 129 (Pt 5): 1081–3. doi:10.1093/brain/awl092. PMID 16627464.{{cite journal}}: CS1 maint: date and year (link)
  29. ^ Abrams D, Jay C, Shade S, Vizoso H, Reda H, Press S, Kelly M, Rowbotham M, Petersen K (2007). "Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial". Neurology. 68 (7): 515–21. doi:10.1212/01.wnl.0000253187.66183.9c. PMID 17296917. S2CID 4845241.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  30. ^ Frank B, Serpell MG, Hughes J, Matthews JN, Kapur D (2008). "Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study". BMJ. 336 (7637): 199–201. doi:10.1136/bmj.39429.619653.80. PMC 2213874. PMID 18182416.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  31. ^ Campbell FA, Tramèr MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ (2001). "Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review". BMJ. 323 (7303): 13–6. doi:10.1136/bmj.323.7303.13. PMC 34324. PMID 11440935.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  32. ^ Wallace M, Schulteis G, Atkinson JH; et al. (2007). "Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers". Anesthesiology. 107 (5): 785–96. doi:10.1097/01.anes.0000286986.92475.b7. PMID 18073554. S2CID 15517673. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  33. ^ "Sativex - Investigational Cannabis-Based Treatment for Pain and Multiple Sclerosis Drug Development Technology". www.drugdevelopment-technology.com. Retrieved 2008-08-08.
  34. ^ Vickers SP, Kennett GA (March 2005). "Cannabinoids and the regulation of ingestive behaviour". Curr Drug Targets. 6 (2): 215–23. doi:10.2174/1389450053174514. PMID 15777191.{{cite journal}}: CS1 maint: date and year (link)
  35. ^ Ranoux D, Attal N, Morain F, Bouhassira D (September 2008). "Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain" (PDF). Annals of Neurology. 64 (3): 274–83. doi:10.1002/ana.21427. PMID 18546285. S2CID 205341110.{{cite journal}}: CS1 maint: date and year (link) CS1 maint: multiple names: authors list (link)
  36. ^ Naumann M, So Y, Argoff CE; et al. (May 2008). "Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology". Neurology. 70 (19): 1707–14. doi:10.1212/01.wnl.0000311390.87642.d8. PMID 18458231. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: date and year (link) CS1 maint: multiple names: authors list (link)
  37. ^ Nelson KA, Park KM, Robinovitz E, Tsigos C, Max MB (1997). "High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia". Neurology. 48 (5): 1212–8. doi:10.1212/wnl.48.5.1212. PMID 9153445. S2CID 25663595.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  38. ^ Head KA (2006). "Peripheral neuropathy: pathogenic mechanisms and alternative therapies" (PDF). Altern Med Rev. 11 (4): 294–329. PMID 17176168.
  39. ^ a b Foster TS (2007). "Efficacy and safety of alpha-lipoic acid supplementation in the treatment of symptomatic diabetic neuropathy". Diabetes Educ. 33 (1): 111–7. doi:10.1177/0145721706297450. PMID 17272797. S2CID 22801230. ALA appears to improve neuropathic symptoms and deficits when administered via parenteral supplementation over a 3-week period. Oral treatment with ALA appears to have more conflicting data whether it improves sensory symptoms or just neuropathic deficits alone.
  40. ^ Ziegler D, Ametov A, Barinov A; et al. (2006). "Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial". Diabetes Care. 29 (11): 2365–70. doi:10.2337/dc06-1216. PMID 17065669. S2CID 16659120. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  41. ^ Patton LL, Siegel MA, Benoliel R, De Laat A (2007). "Management of burning mouth syndrome: systematic review and management recommendations". Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 103 Suppl: S39.e1–13. doi:10.1016/j.tripleo.2006.11.009. PMID 17379153.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  42. ^ Stracke H, Lindemann A, Federlin K (1996). "A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy". Exp. Clin. Endocrinol. Diabetes. 104 (4): 311–6. doi:10.1055/s-0029-1211460. PMID 8886748.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  43. ^ Thornalley PJ (2005). "The potential role of thiamine (vitamin B(1)) in diabetic complications". Curr Diabetes Rev. 1 (3): 287–98. doi:10.2174/157339905774574383. PMID 18220605.
  44. ^ Chen H, Lamer TJ, Rho RH; et al. (2004). "Contemporary management of neuropathic pain for the primary care physician". Mayo Clin. Proc. 79 (12): 1533–45. doi:10.4065/79.12.1533. PMID 15595338. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  45. ^ Kerns JW, White A, Nashelsky J, Sherman S (2006). "Does psychiatric treatment help patients with intractable chronic pain?". J Fam Pract. 55 (3): 235–6. PMID 16510058.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  46. ^ Burke T. "Part 9. How Light (Photo Energy) May Increase Local NO and Vasodilation". Nitric Oxide and Its Role in Health and Diabetes. Diabetes In Control. Retrieved 2008-03-28.
  47. ^ Lavery LA, Murdoch DP, Williams J, Lavery DC (2008). "Does anodyne light therapy improve peripheral neuropathy in diabetes? A double-blind, sham-controlled, randomized trial to evaluate monochromatic infrared photoenergy". Diabetes Care. 31 (2): 316–21. doi:10.2337/dc07-1794. PMID 17977931. S2CID 15382069.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  48. ^ Krames ES. Neuromodulatory devices are part of our "Tools of the Trade". Pain Med 2006;7:S3-5.
  49. ^ Turner JA, Loeser JD, Deyo RA, Sanders SB (2004). "Spinal cord stimulation for patients with failed back surgery syndrome or complex regional pain syndrome: a systematic review of effectiveness and complications". Pain. 108 (1–2): 137–47. doi:10.1016/j.pain.2003.12.016. PMID 15109517. S2CID 16722691.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  50. ^ Lynch SS, Cheng CM, Yee JL (2006). "Intrathecal ziconotide for refractory chronic pain". Ann Pharmacother. 40 (7–8): 1293–300. doi:10.1345/aph.1G584. PMID 16849624. S2CID 1159955.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  51. ^ Turner JA, Sears JM, Loeser JD (2007). "Programmable intrathecal opioid delivery systems for chronic noncancer pain: a systematic review of effectiveness and complications". Clin J Pain. 23 (2): 180–95. doi:10.1097/01.ajp.0000210955.93878.44. PMID 17237668. S2CID 22913374.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  52. ^ Brown JA, Pilitsis JG. Motor Cortex Stimulation Pain Medicine 2006; 7:S140.
  53. ^ Osenbach, R. Neurostimulation for the Treatment of Intractable Facial Pain Pain Medicine 2006; 7:S126
  54. ^ Bittar RG, Kar-Purkayastha I, Owen SL; et al. (2005). "Deep brain stimulation for pain relief: a meta-analysis". J Clin Neurosci. 12 (5): 515–9. doi:10.1016/j.jocn.2004.10.005. PMID 15993077. S2CID 24246117. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  55. ^ Oh MY, Abosch A, Kim SH, Lang AE, Lozano AM (2002). "Long-term hardware-related complications of deep brain stimulation". Neurosurgery. 50 (6): 1268–74, discussion 1274–6. doi:10.1097/00006123-200206000-00017. PMID 12015845. S2CID 36904630.{{cite journal}}: CS1 maint: multiple names: authors list (link)
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Neurotip/Neuropathy/Neuropathic_pain&oldid=1095506700"